Trial Profile
A Randomized, Open-label, Three-arm, Multi-center Phase II Trial of Addition of DCVAC/OvCa to First Line Standard Chemotherapy in Women With Newly Diagnosed Epithelial Ovarian Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs DCVAC OvCa (Primary) ; Carboplatin; Paclitaxel
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors SOTIO
- 16 Feb 2022 Status changed from active, no longer recruiting to completed.
- 16 Feb 2022 This trial has been completed in Poland (Global end date: 18 Nov 2021).
- 22 Jan 2022 This trial has been completed in Czech Republic (Date of the global end of the trial : 18-Nov-2021), according to European Clinical Trials Database record.